News

Cure Alzheimer's Fund Welcomes New Research Management Leader

Cure Alzheimer's Fund Welcomes New Research Management Leader

Cure Alzheimer's Fund Welcomes New Research Management Leader

Cure Alzheimer's Fund is thrilled to announce the appointment of Natasha Hussain, Ph.D., as the new Executive Vice President for Research Management. In her new role, Dr. Hussain is poised to manage and enhance the research opportunities and funding initiatives within the organization.

Bringing Expertise to Alzheimer’s Research

Dr. Hussain will play a crucial role in introducing innovative ideas and perspectives to the organization's research portfolio. Her experience will be invaluable as she collaborates with the scientific community to further Cure Alzheimer's Fund's mission: to prevent, slow, or reverse Alzheimer’s disease.

A Strong Background in Neuroscience

According to Meg Smith, the CEO of Cure Alzheimer's Fund, "Dr. Hussain's experience accelerating discovery and innovation in brain health aligns closely with our mission. Her leadership will help strengthen our work and foster collaborations across the scientific community as we continue advancing Alzheimer's research. We are delighted to welcome her to the CureAlz team."

Dr. Hussain brings with her extensive experience in advancing neuroscience and cross-disciplinary research initiatives. Recently, she served as the inaugural Associate Director of the Knight Initiative for Brain Resilience at Stanford University, where her focus was on strategic programming and partnerships aimed at accelerating discovery in brain health and longevity. Before her time at Stanford, she held the position of Scientific Director at the Kavli Neuroscience Discovery Institute at Johns Hopkins University, where she was instrumental in fostering collaboration between neuroscientists, engineers, and data scientists.

Educational Background and Research Contributions

Dr. Hussain's academic journey began at McGill University, where she earned a Bachelor of Science degree in biology and environmental science, followed by a Ph.D. in neurology and neurosurgery. Her academic and professional experiences underscore her commitment to understanding the intricacies of brain function, including conducting postdoctoral research at the MIT Picower Institute for Learning and Memory. Here, she investigated how brain connections can adapt to experiences and the potential disruptions that could lead to disorders such as schizophrenia.

About Cure Alzheimer’s Fund

Cure Alzheimer's Fund is a nonprofit organization dedicated to funding innovative research aimed at preventing, slowing, or reversing Alzheimer’s disease. Since its inception in 2004, the Fund has awarded over 990 grants to more than 320 leading researchers across 18 countries, investing over $230 million in research programs. Their initiatives have led to significant breakthroughs in understanding the causes and pathology of Alzheimer’s disease.

The organization has achieved an impressive 100% score and a Four-Star rating from Charity Navigator for 13 consecutive years, showcasing its commitment to transparency and effective use of donations. Additionally, Cure Alzheimer’s Fund has received a Platinum Seal of Transparency from Candid, ensuring that 100% of general donations are directed to research programs.
For more detailed information, visit CureAlz.org.

Media Contact

For media inquiries, please contact Barbara Chambers at 978-417-9890.

Frequently Asked Questions

Who is Natasha Hussain?

Natasha Hussain, Ph.D., is the new Executive Vice President for Research Management at Cure Alzheimer's Fund, known for her extensive background in neuroscience.

What is the mission of Cure Alzheimer's Fund?

The mission is to fund research that aims to prevent, slow, or reverse Alzheimer's disease, focusing on innovative scientific approaches.

What are the achievements of Cure Alzheimer’s Fund?

The Fund has surpassed $230 million in research funding, awarded over 990 grants, and received high ratings from Charity Navigator.

Where did Dr. Hussain previously work?

Prior to joining Cure Alzheimer's Fund, Dr. Hussain worked at Stanford University and Johns Hopkins University, focusing on brain research and collaborations.

How can I contact Cure Alzheimer's Fund?

You can reach them through media contact Barbara Chambers at 978-417-9890 for any inquiries related to their research and initiatives.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 2

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 2

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 4

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

Insightful Findings on gMG Treatments by UCB at AANEM 2024

Updated Category News Views 127

UCB Highlights Innovations in Generalized Myasthenia Gravis Treatments at AANEM 2024 UCB, a prominent global biopharmaceutical company, is gearing up to present its latest findings in the management of generalized myasthenia gravis (gMG) at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) meeting. The event, which will also feature...

Continue Reading
Lysander Funds Shares New Distributions Estimates for ETFs

Updated Category News Views 131

Lysander Funds Shares New Distributions Estimates Lysander Funds Limited recently made an announcement about the anticipated cash distributions for December 2024 for their exchange-traded funds (ETFs). The focus is on three notable ETFs: Lysander-Slater Preferred Share ActivETF, Lysander-Canso Corporate Treasury ActivETF, and Lysander-Canso Floating Rate ActivETF. Each of...

Continue Reading
Empowering Girls: Pace Center's Initiatives for Growth

Updated Category News Views 350

Introduction to the Capital Campaign Pace Center for Girls Hillsborough is excited to announce its capital campaign aimed at expanding its capacity and enhancing the support provided to girls in the community. Through dedicated efforts such as education, counseling, and training, this campaign signifies a crucial step towards bettering the future for girls in Hillsborough...

Continue Reading
Bank of America Sees Growth in Loans, Deposits Amid Profit Rise

Updated Category News Views 284

Bank of America Reports Increased Earnings and Efficiency Bank of America Corp (NASDAQ: BAC) has announced strong financial results for the second quarter, showcasing impressive growth in loans, deposits, and overall profitability. The bank reported a net income of $7.1 billion, a slight increase from $6.9 billion the previous year, along with an earnings per share (EPS)...

Continue Reading
Investigating Manitex International: A Closer Look at MNTX

Updated Category News Views 72

Examining Fair Treatment for Manitex International Shareholders Ademi LLP has launched an investigation into Manitex International, Inc. (NASDAQ: MNTX) due to concerns about possible breaches of fiduciary duty related to its recent transaction with Tadano. This investigation raises important questions about whether shareholders are being treated fairly in the financial...

Continue Reading